
antibodies -online.com





IL36A/IL1F6 Protein (AA 8-160)



| \sim | | | | | |
|--------|----|---|----|----|----|
| () | \/ | Δ | r١ | /1 | ۱۸ |

| Overview | |
|--------------------------|--|
| Quantity: | 10 μg |
| Target: | IL36A/IL1F6 (IL1F6) |
| Protein Characteristics: | AA 8-160 |
| Origin: | Mouse |
| Source: | Escherichia coli (E. coli) |
| Protein Type: | Recombinant |
| Biological Activity: | Active |
| Application: | Flow Cytometry (FACS), Intracellular Flow Cytometry (ICFC) |
| Product Details | |
| Purity: | > 95 % , as determined by Coomassie stained SDS-PAGE. |
| Sterility: | 0.22 μm filtered |
| Endotoxin Level: | Less than 0.01 ng per µg cytokine as determined by the LAL method. |
| Target Details | |
| Target: | IL36A/IL1F6 (IL1F6) |
| Alternative Name: | IL-36 alpha (IL1F6 Products) |
| Background: | IL-36α is one of the IL-36 cytokines that are part of the IL-1 family. Like other IL-1 family |
| | members, IL-36α requires N-terminal processing to gain full bioactivity. IL-36α signals through |
| | IL-36R/IL-1RAcP, which results in MAPK, Erk1/2, and JNK activation. IL-36α is implicated in skin |
| | homeostasis, and is overexpressed in psoriatic lesional skin. Transgenic mice overexpressing |

| IL-36α in their skin have an inflammatory skin condition showing some characteristics of |
|--|
| human psoriasis, including thickened scaly skin, acanthosis, hyperkeratosis, and dermis |
| infiltration. EGF regulates expression of IL-36α in skin cells. IL-36α can also be detected in |
| adipose tissue where it reduces adipocyte differentiation and also induces inflammatory gene |
| expression in mature adipocytes. In lungs, the expression of IL-36 α is increased in response to |
| inflammatory stimuli. Intratracheal instillation of recombinant mouse IL-36α induces CXCL1 |
| and CXCL2 expression and also neutrophil influx in the lungs. IL-36 α , IL-36 β , and IL-36 γ induce |
| in vitro expression of RNAs of multiple cytokines (IL-6, IL-12 p40, CXCL1, CCL1, IL-12 p35, IL-1 β , |
| IL-19 p19, GM-CSF, CXCL10, TNFa, CCL3, VCAM-1, and ICAM-1) in mouse bone marrow-derived |
| dendritic cells and CD4 T cells obtained from normal mice. IL-36a expression is elevated in |
| chronic kidney disease and in rheumatoid arthritis synovium, and decreased expression |
| correlates with a poor prognosis in hepatocellular carcinomas. |
| |

Molecular Weight:

The 153 amino acid recombinant protein has a predicted molecular mass of approximately 17 kDa. The DTT-reduced and non-reduced protein migrate at approximately 17 kDa by SDS-PAGE. The predicted N-terminal amino acid is Arg.

Pathways:

Cancer Immune Checkpoints

Application Details

| Application Notes: | Optimal working dilution should be determined by the investigator. |
|--------------------|---|
| Comment: | Biological activity: The activity is determined by the dose-dependent stimulation of IL-6 secretion in 3T3L1 preadipocytes. The ED50 is $2 - 10$ ng/ml, corresponding to a specific activity $1 - 5 \times 105$ units/mg. |
| Restrictions: | For Research Use only |

Handling

| Format: | Liquid For maximum results, quick spin vial prior to opening. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C. | |
|------------------|--|--|
| Reconstitution: | | |
| Buffer: | 0.22 μm filtered protein solution is in 20 mM Hepes, pH 7.2, 150 mM NaCl, 10 mM TCEP. | |
| Handling Advice: | Avoid repeated freeze/thaw cycles. | |
| Storage: | -20 °C | |

Handling

Storage Comment:

Unopened vial can be stored between 2°C and 8°C for one week, at -20°C for six months, or at -70°C for one year.